Island Pharmaceuticals (ILA) Stock Overview
A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ILA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Island Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.36 |
| 52 Week High | AU$0.63 |
| 52 Week Low | AU$0.13 |
| Beta | 0.13 |
| 1 Month Change | -5.26% |
| 3 Month Change | -18.18% |
| 1 Year Change | 125.00% |
| 3 Year Change | 400.00% |
| 5 Year Change | 0% |
| Change since IPO | -35.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -2.7% | 1.6% | 0.3% |
| 1Y | 125.0% | -5.4% | 14.0% |
Return vs Industry: ILA exceeded the Australian Pharmaceuticals industry which returned -5.4% over the past year.
Return vs Market: ILA exceeded the Australian Market which returned 14% over the past year.
Price Volatility
| ILA volatility | |
|---|---|
| ILA Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in AU Market | 17.8% |
| 10% least volatile stocks in AU Market | 4.5% |
Stable Share Price: ILA has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ILA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Foster | www.islandpharmaceuticals.com |
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Island Pharmaceuticals Limited Fundamentals Summary
| ILA fundamental statistics | |
|---|---|
| Market cap | AU$106.41m |
| Earnings (TTM) | -AU$7.20m |
| Revenue (TTM) | AU$62.85k |
Is ILA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILA income statement (TTM) | |
|---|---|
| Revenue | AU$62.85k |
| Cost of Revenue | AU$2.05m |
| Gross Profit | -AU$1.99m |
| Other Expenses | AU$5.21m |
| Earnings | -AU$7.20m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | -3,159.34% |
| Net Profit Margin | -11,452.57% |
| Debt/Equity Ratio | 0% |
How did ILA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/18 18:09 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Island Pharmaceuticals Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naheed Rahman | RaaS Advisory Pty Ltd |